PFIZER LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,206 INR | +0.25% |
|
+1.57% | -1.47% |
| 04-02 | Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer | CI |
| 04-02 | Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director Finance | CI |
| Sales 2024 * | 22.01B 264M 21.05B | Sales 2025 * | 23.81B 285M 22.77B | Capitalization | 192B 2.3B 184B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.02B 60.12M 4.8B | Net income 2025 * | 5.88B 70.47M 5.62B | EV / Sales 2024 * | 8.72 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 8.06 x |
| P/E ratio 2024 * |
38.2
x | P/E ratio 2025 * |
32.7
x | Employees | 1,702 |
| Yield 2024 * |
1.22% | Yield 2025 * |
1.12% | Free-Float | 35.19% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.25% | ||
| 1 week | +1.57% | ||
| Current month | +0.29% | ||
| 1 month | -5.47% | ||
| 3 months | -3.04% | ||
| 6 months | +6.66% | ||
| Current year | -1.47% |
1 week
4 092.05
4 277.95
1 month
4 050.104 477.00
Current year
4 050.104 940.00
1 year
3 725.854 940.00
3 years
3 406.956 164.80
5 years
2 797.506 164.80
10 years
1 175.006 164.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 02/04/23 | |
Pankaj Gupta
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 06/12/99 | |
| Director/Board Member | 74 | 20/05/12 | |
| Director/Board Member | 64 | 13/02/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 4,206 | +0.25% | 1 283 |
| 26/04/24 | 4,195 | +1.50% | 1,433 |
| 25/04/24 | 4,133 | +0.30% | 1,089 |
| 24/04/24 | 4,121 | -0.59% | 1,287 |
| 23/04/24 | 4,145 | +0.11% | 924 |
Delayed Quote Bombay S.E., April 29, 2024 at 11:00 am
More quotes
Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.
Sector
Pharmaceuticals
Calendar
28/05/2024
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +26.11% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.60% | 231B | |
| +5.33% | 200B | |
| -8.96% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PFIZER Stock
- PFIZER Stock
